Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-04-05
2011-04-05
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07919100
ABSTRACT:
The present invention concerns a modified polypeptide containing at least an immunodominant region and the connecting loop between N- and C-helices of gp41 ectodomain of HIV-1, wherein the connecting loop includes at least a linker fragment having: —a size convenient for keeping the native conformation of the interaction between N- and C-helices, and —an hydrophily sufficient to provide a soluble and stable trimeric form to said modified polypeptide.
REFERENCES:
patent: 6455265 (2002-09-01), Serres
patent: WO 99/25377 (1999-05-01), None
patent: WO 02/34909 (2002-05-01), None
Desrosiers, R. C., 2004, Prospects for an AIDS vaccine, Nat. Med. 10(3):221-223.
Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet 366:1894-1898.
Burton, D. R., et al., 2004, HIV vaccine design and the neutralizing antibody problem, Nat. Immunol. 5(3):233-236.
Walker, B. D., and D. R. Burton, 2008, Toward an AIDS vaccine, Science 320:760-765.
Louis J M, et al; (2001); “Design and Properties of Nccg-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity”; Journal of Biological Chemistry; vol. (276); pp. 29485-29489.
Eckert D M, et al; (2001); “Design of Potent Inhibitors of HIV-1 Entry From the gp41 N-peptide Region”; Proceedings of the National Academy of Science of USA; vol. (98); pp. 11187-11192.
Root M J, et al; (2001); “Protein Design of an HIV-1 Entry Inhibitor”; Science; vol. (291); pp. 884-888.
Lu M, et al; (1999); “Subdomain Folding and Biological Activity of the Core Structure from Human Immunodeficiency Virus Type 1 gp41: Implications for Viral Membrane Fusion”; Journal of Virology; vol. (73); pp. 4433-4438.
Serres P F; (2001); “AIDS: an Immune Response Against the Immune System. Role of a Precise Tridimensional Molecular Mimicry”; Journal of Autoimmunity; vol. (16); pp. 287-291.
Fleury Sylvain
Girard Marc P
Mouz Nicolas
Roger Marie-Gaëlle
Serres Pierre-François
Mymetics Corporation
Oliff & Berridg,e PLC
Parkin Jeffrey S.
LandOfFree
Soluble and stabilized trimeric form of gp41 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble and stabilized trimeric form of gp41 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble and stabilized trimeric form of gp41 polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641662